Medivation's Dimebon turns in promising results for Huntington's

The drug Dimebon, which has shown some significant promise for Alzheimer's, has now registered positive results in a trial designed to test the therapy's ability to improve thinking, learning and memory skills for people who suffer from Huntington's. Dr. Karl Kieburtz of the University of Rochester in New York says that the drug also appears to be safe and well tolerated. Article